Infectious Diseases in Toxic Epidermal Necrolysis

  • José M. Arévalo
  • José A. Lorente
  • Carlos González-Herrada
  • José Jiménez-Reyes
  • Carlos Santonja
  • Paloma Garcia-Hierro


Lyell’s syndrome or toxic epidermal necrolysis (TEN) is a diffuse exfoliative cutaneous disease with systemic involvement. The initial pathogenic mechanism involves T-cell mediated immunological skin damage triggered by the ingestion of drugs. The key subsequent event is an extensive epidermal detachment from the underlying dermis and exposure of extensive areas of denuded skin, inducing pathophysiological changes similar to those observed in superficial dermal burns. The disease is also characterized by loss of mucosal membranes, fever, systemic toxicity and an increased risk of infection and respiratory failure. Complications of TEN are similar to those observed in burned patients, including repeated episodes of sepsis and bacteremia, shock and sequential organ dysfunction.


Body Surface Area Graft Versus Host Disease Toxic Epidermal Necrolysis Human Immune Deficiency Virus Erythema Multiforme 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lyell A Toxic epidermal necrolysis an eruption resembling scalding of the skin. Br J Dermatol 68:355, 1956.PubMedCrossRefGoogle Scholar
  2. 2.
    Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 129:92, 1993.PubMedCrossRefGoogle Scholar
  3. 3.
    Patterson R, Dykewicz MS, Gonzales A. Erythema multiforme and Stevens-Johnson syndrome: descriptive and therapeutic controversy. Chest 98:331, 1990.PubMedCrossRefGoogle Scholar
  4. 4.
    Wilkins J, Morrison L, White CR. Oculocutaneous manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Dermatol Cline 10:571, 1992.Google Scholar
  5. 5.
    Roujeau JC, Kelly JP, Nalco L. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333:1600, 1995.PubMedCrossRefGoogle Scholar
  6. 6.
    Chan HL, Stern RS, Ardnt KA. The incidence of erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 126:43, 1990.PubMedCrossRefGoogle Scholar
  7. 7.
    Zoltie N, Verlende P, O’Neill S, McKenzie AW. Lyell’s syndrome on a burn unit. Burns 204:368, 1994.CrossRefGoogle Scholar
  8. 8.
    Kelemen III JJ, Cioffi WC, McManus WF, Mason AD, Pruitt BA. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg 180:273, 1995.PubMedGoogle Scholar
  9. 9.
    Halebian PH, Madden MR, Finkelstein JL. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 204:503, 1986.PubMedCrossRefGoogle Scholar
  10. 10.
    Herndon DN. Toxic epidermal necrolysis: a systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids. J Am Coll Surg 180:340, 1995.PubMedGoogle Scholar
  11. 11.
    Revuz J, Penson D, Roujeau JC. Toxic epidermal necrolysis: clinical findings and prognostic factors in 87 patients. Arch Dermatol 123:1160, 1987.PubMedCrossRefGoogle Scholar
  12. 12.
    Roujeau JC, Stern RS. Severe cutaneous adverse reactions to drugs. N Engl J Med 331:1272, 1994.PubMedCrossRefGoogle Scholar
  13. 13.
    Correia O, Chosidow O, Saiag P, Bastuji-Garin S, Revuz J, Roujeau JC. Evolving pattern of drug induced toxic epidermal necrolysis. Dermatology 186:32, 1993.PubMedCrossRefGoogle Scholar
  14. 14.
    Prendiville JS, Hebert AA, Greewald MJ, Esterly NB. Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr 115:881, 1987.Google Scholar
  15. 15.
    Saiag P, Caumes E, Chosidow O. Drug induced toxic epidermal necrolysis (Lyell’s syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol 26:567, 1992.PubMedCrossRefGoogle Scholar
  16. 16.
    Roujeau JC, Revuz J. Toxic epidermal necrolysis: An expanding field of knowledge. J Am Acad Dermatol 31:301, 1994.PubMedCrossRefGoogle Scholar
  17. 17.
    Parsons JM. Toxic epidermal necrolysis. Int J Dermatol 31:749, 1992.PubMedCrossRefGoogle Scholar
  18. 18.
    Peck GL, Herzig GP, Elias PM. Toxic epidermal necrolysis in a patient with graft vs host reaction. Arch Dermatol 105:561, 1972.PubMedCrossRefGoogle Scholar
  19. 19.
    Avakian R, Flowers FP, Araujo OE, Ramos Careo FA. Toxic epidermal necrolysis: A review. J Am Acad Dermatol 25:69, 1991.PubMedCrossRefGoogle Scholar
  20. 20.
    Arévalo JM, Lorente JA. Necrolisis epidérmica tóxica. Tendencias terapeuticas. Anales de Medicina Interna (Madrid, Spain) (in Spanish) 15:67, 1998.Google Scholar
  21. 21.
    Chosidow O, Delcjier JG, Chaumette MT Intestinal involvement in drug-induced toxic epidermal necrolysis. Lancet 337:923, 1991.CrossRefGoogle Scholar
  22. 22.
    Whale D, Beste D, Conley SF. Laryngeal involvement in toxic epidermal necrolysis. Otolaryngol Head Neck Surg 6:796, 1992.Google Scholar
  23. 23.
    Lebargy F, Wolkenstein P, Gisselbrecht M, Lange F, Fleury-Feith J. Pulmonary complications in toxic epidermal necrolysis: A prospective clinical study. Intensive Care Med 23:1237, 1997.PubMedCrossRefGoogle Scholar
  24. 24.
    Villada G, Roujeau JC, Clérici T, Bourgault Y, Revuz J. Immunopathology of toxic epidermal necrolysis. Arch Dermatol 128:50, 1992.PubMedCrossRefGoogle Scholar
  25. 25.
    Paquet P, Pierard GE. Erythema multiforme and toxic epidemal necrolysis: A comparative study. Am J Dermatol 19:127, 1997.CrossRefGoogle Scholar
  26. 26.
    Roujeau JC, Chosidow O, Saiag P, Guillaume JC. Toxic epidermal necrolysis (Lyell’s syndrome). J Am Acad Dermatol 23:1039, 1990.PubMedCrossRefGoogle Scholar
  27. 27.
    Arévalo JM, Lorente JA. Fiebre y leucopenia en un paciente con rash maculopapular progresivo tras un proceso gripal. In Rello J, Vallés J (eds). Casos clínicos en infecciones graves. Trucos y trampas. Barcelona: Edika Med, 1998: 23.Google Scholar
  28. 28.
    Green D, Law E, Still M. An approach to the management of toxic epidermal necrolysis in a burn center. Burns 195:411, 1993.CrossRefGoogle Scholar
  29. 29.
    Bone RC, Balk RA, Cerra FB. The ACCP/SCCM consensus conference committe. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies. Chest 101:1644, 1992.PubMedCrossRefGoogle Scholar
  30. 30.
    Marshall JC. Criteria for the description of organ dysfunction in sepsis and SIRS. In Fein AM, Abraham EM, Balk RA, Bernard GR, Bone RC, Dantzer DR, Fink MP (eds). Sepsis and multiorgan failure. Baltimore: Williams and Wilkins, 1997: 286.Google Scholar
  31. 31.
    Halebian P, Corder V, Herndon DN. A burn center experience with toxic epidermal necrolysis. J Burn Care Rehabil 4:176, 1983.CrossRefGoogle Scholar
  32. 32.
    Khoo AKM, Foo CL. Toxic epidermal necrolysis in a burn center: A 6 year review. Burns 22:275, 1996.PubMedCrossRefGoogle Scholar
  33. 33.
    Heimbach DM, Engrav LV, Marvin JA. Toxic epidermal necrolysis: A step forward in treatment. JAMA 257:2171, 1987.PubMedCrossRefGoogle Scholar
  34. 34.
    Kucan JO. Use of Biobrane in the treatment of toxic epidermal necrolysis. J Burn Care Rehabil 16:324, 1995.PubMedCrossRefGoogle Scholar
  35. 35.
    Arévalo JM, Lorente JA, Gordo F, Tejedor C, Pascual T, Esteban A. Cambios en la perfusión de la mucosa intestinal inducidos por dobutamina en pacientes quemados críticos. Medicina Inten-siva (Barcelona) 21:147, 1997.Google Scholar
  36. 36.
    Lorente JA, Ezpeleta A, Esteban A, Arévalo JM. Hemodynamic and gastric pCO2 changes in critically ill burned patients. Crit Care Med, 28:1728–1735, 2000.PubMedCrossRefGoogle Scholar
  37. 37.
    Timsit JF, Mion G, Gulluche YL. Severe hypothermia occurring during the course of toxic epidermal necrolysis in patients treated with air fluidized beds. Arch Dermatol 127:147, 1991.CrossRefGoogle Scholar
  38. 38.
    Arévalo JM, Lorente JA. Tratamiento de la necrolisis epidérmica tíxica. Med Clin (Bare) 111:27, 1998.Google Scholar
  39. 39.
    Finlay AY, Richards J, Holt PJA. Intensive therapy unit management of toxic epidermal necrolysis: Practical aspects. Clin Exp Dermatol 7:55, 1982.PubMedCrossRefGoogle Scholar
  40. 40.
    Management of toxic epidermal necrolysis (editorial). Lancet 2:1250, 1984.Google Scholar
  41. 41.
    Marvin JA, Heimbach DM, Engrav LH, Harner TJ. Improved treatment of Stevens-Johnson syndrome. Arch Surg 119:601, 1984.PubMedCrossRefGoogle Scholar
  42. 42.
    Canoso JJ, Barza M. Soft tissue infections. Rheum Dis Clin North Am 15:235, 1993.Google Scholar
  43. 43.
    Lorente JA, Gordo F, Arévalo JM. Cambios hemodinámicos en pacientes con quemaduras. In Lorente JA, Esteban A (eds). Cuidados intensivos del paciente quemado. Barcelona: Springer Verlag Ibérica, 1998: 353.Google Scholar
  44. 44.
    González-Arévalo A, Caro MM, Ortigosa E. Analgesia del paciente quemado. In Lorgnette JA, Esteban A (eds). Cuidados intensivos del paciente quemado. Barcelona: Springer Verlag Ibérica, 1998: 489Google Scholar
  45. 45.
    Velasco P, Garcia E, Abad E, Lorente JA, Arévalo JM, Casado S. Cuidados de enfermería en el paciente con necrolisis epidérmica tóxica. Enferm Intensiva 10:174, 1999.Google Scholar
  46. 46.
    Bjornberg A, Bjornberg K, Gisslen H. Toxic epidermal necrolysis with ophthalmic complications. Acta Opthalmol 42:1084, 1964.CrossRefGoogle Scholar
  47. 47.
    Howard GM. The Stevens-Johnson syndrome, ocular prognosis and treatment. Am J Ophthalmol 55:893, 1963.PubMedGoogle Scholar
  48. 48.
    Roujeau JC, Koso M, Andre C. Sjögren-like syndrome after drug induced toxic epidermal necrolysis. Lancet 2:609, 1985.CrossRefGoogle Scholar
  49. 49- Lyell A. Toxic epidermal necrolysis, the scalded syndrome: a reappraisal. Br J Dermatol 100:69, 1979.PubMedCrossRefGoogle Scholar
  50. 50.
    Revuz J, Roujeau JC, Guillaume JC. Treatment of toxic epidermal necrolysis. Creteil’s experience. Arch Dermatol 123:1156, 1987.PubMedCrossRefGoogle Scholar
  51. 51.
    Serfling S. Sudden onset of blisters and ulcerations in a healthy man. Arch Dermatol 129:776, 1993.PubMedCrossRefGoogle Scholar
  52. 52.
    Tegelberg-Stassen MJAM, van Vloten WA, de la Faille HB. Management of non-staphilococcal toxic epidermal necrolysis: follow up study of 16 case histories. Dermatologica 180:124, 1990.PubMedCrossRefGoogle Scholar
  53. 53.
    Parsons JM. Management of toxic epidermal necrolysis. Cutis 36:305, 1985.PubMedGoogle Scholar
  54. 54.
    Madalene C, Sunni G. Efficacy of cyclophosphamide in toxic epidermal necrolysis. J Am Acad Dermatol 25:778, 1991.CrossRefGoogle Scholar
  55. 55.
    Razzaque AA, Hombal GM. Cyclophosphamide (Cytosan). J Am Acad Dermatol 11:111, 1984.CrossRefGoogle Scholar
  56. 56.
    Hertl M, Bohlen H, Merk HE Efficacy of cyclophosphamide in toxic epidermal necrolysis. J Am Acad Dermatol 129:92, 1993.Google Scholar
  57. 57.
    González-Herrada CM, Jiménez-Reyes J. Necrolisis epidérmica tóxica (síndrome de Lyell). In Lorente JA, Esteban A (eds). Cuidados intensivos del paciente quemado. Barcelona: Springer Verlag Ibérica, 1998: 63.Google Scholar
  58. 58.
    Biren CA, Barr RJ. Dermatologic applications of cyclosporin A. Arch Dermatol 122:1028, 1986.PubMedCrossRefGoogle Scholar
  59. 59.
    Wagner H. Cyclosporin A: Mechanism of action. Transplant Proc 25:523, 1983.Google Scholar
  60. 60.
    Fredane LM, McCabe RE. The effect of cyclosporin A on lymphocyte subset in experimental allergic encephalomyelitis: functional loss of disease-supressing cells in vivo. Transplant Proc 15:2909, 1983.Google Scholar
  61. 61.
    Renfro L, Grant-Kels JM, Daman LA. Drug induced toxic epidermal necrolysis treated with cyclosporin A. Intern J Derm 28:441, 1989.CrossRefGoogle Scholar
  62. 62.
    Hewitt J, Ormerod AD. Toxic epidermal necrolysis treated with cyclosporin A. Clin Exp Derm 17:264, 1992.PubMedCrossRefGoogle Scholar
  63. 63.
    Szepietwski J, Wasik F, Szybejko-Machaj G, Maj M. Toxic epidermal necrolysis successfully treated with cyclosporin A. Report of three cases. J Eur Acad Dermatol Veneorol 9:169, 1997.CrossRefGoogle Scholar
  64. 64.
    Zaki Y, Patel S, Reed R, Dalziel KL. Toxic epidermal necrolysis associated with severe hypocalcemia and treated with cyclosporin A. British J Derm 133:329, 1995.CrossRefGoogle Scholar
  65. 65.
    Jarret P, Rademaker M, Havill J, Pullon H. Toxic epidermal necrolysis treated with cyclosporin A and granulocyte colony stimulating factor. Clin Exp Dermatol 22:146, 1997.CrossRefGoogle Scholar
  66. 66.
    Jarret P, Ha T, Snow J. Toxic epidermal necrolysis and cyclosporin A. Clin Exp Dermatol 22: 254, 1997.CrossRefGoogle Scholar
  67. 67.
    Sullivan JR, Watson A. Lamotrigine induced toxic epidermal necrolysis treated with intravenous cyclosporin A: A discussion of pathogenesis and immunosupressive management. Austr J Dermatol 37:208, 1996.CrossRefGoogle Scholar
  68. 68.
    Arévalo JM, Lorente JA, González-Herrada CM, Jiménez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma, 48: 473–478, 2000.PubMedCrossRefGoogle Scholar
  69. 69.
    Taylor JA, Grube B, Heimbach DM. Toxic epidermal necrolysis, a comprehensive approach multidisciplinary management in a burn center. Clin Pediatr 28:404, 1989.CrossRefGoogle Scholar
  70. 70.
    Roher TE, Ahmed R. Toxic epidermal necrolysis. Int J Dermatol 30:457, 1991.CrossRefGoogle Scholar
  71. 71.
    Yarbrough DR. Experience with toxic epidermal necrolysis treated in a burn center. J Burn Care Rehabil 17:30, 1996.PubMedCrossRefGoogle Scholar
  72. 72.
    Prasad JK, Feller I, Thompson PD. Use of amnion for the treatment of Stevens-Johnson syndrome. J Trauma 26:945, 1986.PubMedCrossRefGoogle Scholar
  73. 73.
    Bishop JF, Demling RH, Hansbrough JF, Hansbrough W, Kucan JO, Rodeheaver GT, et al. Indications for use of Biobrane in wound management. J Burn Care Rehabil 16:341, 1995.CrossRefGoogle Scholar
  74. 74.
    Rodeheaver GT, Harstell MS, Brent C. Influence of Biobrane construction on adherence. J Burn Care Rehabil 16:321, 1995.PubMedCrossRefGoogle Scholar
  75. 75.
    Smith DJ. Use of Biobrane in wound management. J Burn Care Rehabil 16:317, 1995.PubMedCrossRefGoogle Scholar
  76. 76.
    Arévalo JM, Gaos L, Lorente J A. Cobertura de la quemadura. In Lorente J A, Esteban A (eds). Cuidados intensivos del paciente quemado. Barcelona: Springer Verlag Iberica, 1998: 156.Google Scholar
  77. 77.
    Sowder LL. Biobrane wound dressing used in the treatment of toxic epidermal necrolysis: a case report. J Burn Care Rehabil 11:237, 1990.PubMedCrossRefGoogle Scholar
  78. 78.
    Arévalo JM, Lorente JA. Skin coverage with Biobrane biomaterial for the treatment of patients with toxic epidermal necrolysis. J Burn Care Rehabil 20:406, 1999.PubMedCrossRefGoogle Scholar
  79. 79.
    Al-Qattan MM. Toxic epidermal necrolysis: a review and report of the successfull use of Biobrane for early wound coverage. Ann Plast Surg 36:224, 1996.PubMedCrossRefGoogle Scholar
  80. 80.
    Pruitt BA, Levine NS. Characteristics and uses of biologic dressings and skin substitutes. Arch Surg 119:312, 1984.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • José M. Arévalo
  • José A. Lorente
  • Carlos González-Herrada
  • José Jiménez-Reyes
  • Carlos Santonja
  • Paloma Garcia-Hierro

There are no affiliations available

Personalised recommendations